Terms: = Ovarian cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Treatment
9 results:
1. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
2. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
[TBL] [Abstract] [Full Text] [Related]
3. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in ovarian cancer.
Lakis S; Kotoula V; Koliou GA; Efstratiou I; Chrisafi S; Papanikolaou A; Zebekakis P; Fountzilas G
Cancer Genomics Proteomics; 2020; 17(5):529-541. PubMed ID: 32859631
[TBL] [Abstract] [Full Text] [Related]
4. Targeting the centriolar replication factor stil synergizes with DNA damaging agents for treatment of ovarian cancer.
Rabinowicz N; Mangala LS; Brown KR; Checa-Rodriguez C; Castiel A; Moskovich O; Zarfati G; Trakhtenbrot L; Levy-Barda A; Jiang D; Rodriguez-Aguayo C; Pradeep S; van Praag Y; Lopez-Berestein G; David A; Novikov I; Huertas P; Rottapel R; Sood AK; Izraeli S
Oncotarget; 2017 Apr; 8(16):27380-27392. PubMed ID: 28423708
[TBL] [Abstract] [Full Text] [Related]
5. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract] [Full Text] [Related]
6. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract] [Full Text] [Related]
7. Clinical implication of serum sil-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract] [Full Text] [Related]
8. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Freedman RS; Gibbons JA; Giedlin M; Kudelka AP; Kavanagh JJ; Edwards CL; Carrasco CH; Nash MA; Platsoucas CD
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):443-51. PubMed ID: 9041464
[TBL] [Abstract] [Full Text] [Related]
9. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
[TBL] [Abstract] [Full Text] [Related]
